Moderna, Merck combo cancer-vaccine treatment shows ‘significant’ promise
A cancer vaccine developed by Moderna Inc. and Merck & Co. Inc. showed promising results in a key study, reducing…
39,500€
9,36%
Echtzeit-Aktienkurs Moderna Inc.
Bid:
Ask:
Nachrichten zur Moderna Inc. Aktie
UPDATE 1-Moderna/Merck cancer vaccine plus Keytruda delays skin cancer return
... Steenhuysen and Michael Erman
April 16 (Reuters) - An experimental mRNA cancer......…
Moderna Shows Progress Toward Cancer Vaccines
An mRNA shot helped prevent relapse in high-risk melanoma patients....…
Merck-Moderna Vaccine Helps Keytruda Keep Melanoma Patients ...
Um den gesamten Artikel unter news.google.com zu lesen, klicken Sie bitte auf die Überschrift...…
Moderna, Inc.: Moderna and Merck Announce mRNA-4157 , an Investigational Individualized Neoantigen Therapy, in Combination with KEYTRUDA , Demonstrated Superior Recurrence-Free Survival in Patients with High-Risk Stage III/IV Melanoma Following Compl
mRNA-4157 (V940) in combination with KEYTRUDA reduced the risk of recurrence or death by 44% compared to KEYTRUDA alone in…
Catalent warns of production issues, finishes day as worst S&P 500 performer
CNBC's Meg Tirrell joins 'Closing Bell: Overtime' to report on Catalent and Moderna....…
Insiderhandel: Chief Executive Officer verkauft Aktien von Moderna im Wert von 6.430.340$
Bancel, Stephane - Vorstand - Tag der Transaktion: 2023-04-13...…
Insiderhandel: Chief Executive Officer verkauft Aktien von Moderna im Wert von 6.267.336$
Bancel, Stephane - Vorstand - Tag der Transaktion: 2023-04-12...…
Dow & Co grenzen Verluste ein: JPMorgan, Alphabet und Nvidia unter den Top-Werten, Boeing, UnitedHealth, Moderna, Netflix und Rivian geben deutlich nach – der Tag an der Wall Street
Kursgewinne im US-Finanzsektor nach starken Geschäftszahlen von Banken haben am Freitag die US-Aktienindizes nicht vor Verlusten geschützt. Der Grund waren…
Moderna Inc. stock underperforms Friday when compared to competitors
Moderna Inc. stock underperforms Friday when compared to competitors...…
Moderna: Vaccines Day hinterlässt mehr Fragen als Antworten - Aktienanalyse
Charlotte (www.aktiencheck.de) - Moderna-Aktienanalyse von BofA Securities:
Die Analysten von BofA Securities stufen die Aktie von Moderna Inc. (ISIN: US60770K1079, WKN:…
Moderna Inc. stock outperforms competitors on strong trading day
Moderna Inc. stock outperforms competitors on strong trading day...…
Biotech Stock Roundup: MRNA Provides Update, KALA, IFRX Surge on Regulatory News
Regulatory and pipeline updates from Moderna (MRNA) and KALA are the key highlights for the biotech sector....…
Can Pfizer Beat GSK and Moderna in This $10 Billion Market?
Theres such a big need in preventing RSV that multiple companies should be big winners....…
Moderna (MRNA) Gains As Market Dips: What You Should Know
In the latest trading session, Moderna (MRNA) closed at $155.56, marking a +0.2% move from the previous day....…
Moderna (MRNA) Posts 2027 Biz View, Down 3% on Flu Jab Setback
Moderna (MRNA) expects $8-$15 billion in product revenues from the respiratory vaccine by 2027. Its first influenza vaccine candidate failed…
US Court Favors Moderna In COVID-19 Vaccine Patent Infringement Case With Arbutus Biopharma
read more...…
Moderna eyes local COVID vaccines for Japan, other countries
Um den gesamten Artikel unter asia.nikkei.com zu lesen, klicken Sie bitte auf die Überschrift...…
Insiderhandel: Chief Executive Officer verkauft Aktien von MRNA im Wert von 6.298.950$
Bancel, Stephane - Vorstand - Tag der Transaktion: 2023-04-06...…
Insiderhandel: Chief Executive Officer verkauft Aktien von MRNA im Wert von 6.185.585$
Bancel, Stephane - Vorstand - Tag der Transaktion: 2023-04-05...…
22-Year-Old National Guard Soldier Suffers Two Heart Attacks, Neurological Issues After Moderna Vax
22-Year-Old National Guard Soldier Suffers Two Heart Attacks, Neurological Issues After Moderna Vax
…
Moderna Inc. stock falls Tuesday, underperforms market
Moderna Inc. stock falls Tuesday, underperforms market...…
Dow im Plus, Tech-Werte im Minus, US-Leitzins im Fokus, Caterpillar, Nike, Carmax, Lucid und Tesla top, Microsoft und Moderna schwach – der Tag an der Wall Street
Die US-Aktienmärkte haben sich am Dienstag in unterschiedliche Richtungen bewegt. Insgesamt dominierte im späten Handel die Vorsicht. So dämmte der…
Moderna, TSR fall; CarMax, Coinbase rise
Stocks that traded heavily or had substantial price changes Tuesday: Moderna, TSR fall; CarMax, Coinbase rise...…
Moderna wins appeal court ruling in Arbutus COVID vaccine patent dispute
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Moderna fends off Arbutus appeal in COVID-19 vaccine patent fight
...By Blake Brittain
(Reuters) - A U.S. appeals court handed Moderna......…
Stocks making the biggest moves midday: WW International, CarMax, Mohawk, Moderna and more
These are the stocks posting the largest moves in midday trading....…
Moderna says there are not enough cases to declare early success for its mRNA flu vaccine
CNBC's Meg Tirrell reports on news from Moderna that it will delay results from its flu vaccine trials....…
«Moderna ist auf gutem Weg, eines der grossen Pharmaunternehmen zu werden»
BB-Biotech-Investmentchef Daniel Koller - Für Daniel Koller, Anlagechef von BB Biotech, sind mehr als nur sinkende Zinsen notwendig, dass Biotech-Aktien…
Blitz-Update: Dow & S&P 500 im Plus, Lucid Group, Tesla, CarMax und Caterpillar stark, Moderna, Microsoft, Salesforce und Amazon schwach
Die US-Aktienmärkte haben am Dienstag zur Eröffnung keine großen Sprünge gemacht. Potenziell marktbewegende Konjunkturdaten stehen nicht auf der Agenda. Jedoch…
BioNTech-Konkurrent Moderna: Enttäuschung bei Grippeimpfstoff – Aktie knickt ein
Bei Moderna findet heute der „Vaccine Day“ statt. Auf der jährlichen Veranstaltung präsentiert das Unternehmen Updates zur Impfstoffentwicklung. Beim Grippeimpfstoff…
Could Moderna Become a Warren Buffett Stock?
It depends on how effectively it spins up streams of recurring revenue....…
Vaccines For Lyme Disease And Norovirus? Moderna Working On Shots Targeting Tick-Borne Infection And Vomiting Bug
Lyme is Modernas first attempt at creating a vaccine for a bacterial infection....…
Moderna Stock Slides Despite Positive Vaccines Update. Heres Why.
The biotech company is working on new drugs for Lyme disease and Covid-19 as it prepares to roll out six…
Moderna says potential flu vaccine needs more study
Moderna shares slipped Tuesday morning after the COVID-19 vaccine developer said its potential flu vaccine needs more study in a…
Stocks making the biggest moves premarket: Moderna, CarMax, Whirlpool and more
CarMax soared on the back of better-than-expected quarterly earnings....…
Moderna Expects 6 Major Vaccine Launches In Next Few Years
Moderna Expects 6 Major Vaccine Launches In Next Few Years...…
Moderna to Push Backup Experimental Flu Shot After Setback
Um den gesamten Artikel unter news.google.com zu lesen, klicken Sie bitte auf die Überschrift...…
Moderna is developing a vaccine candidate against Lyme disease that would be its first bacterial vaccine
Moderna Inc. MRNA outlined its clinical goals for its mRNA platform on Tuesday to mark its 4th Vaccine Day, including…
Moderna, Inc.: Moderna Announces Clinical and Program Updates at 4th Vaccines Day
Next-generation, refrigerator-stable COVID-19 vaccine candidate, mRNA-1283, has dosed first participant in its Phase 3 trialCompany expects to file for approval…
Moderna Inc. stock outperforms competitors on strong trading day
Moderna Inc. stock outperforms competitors on strong trading day...…
Moderna says it hopes to offer new vaccines for cancer, heart disease, and other conditions by 2030
Modernas chief medical officer said advancements in mRNA technology since the outset of the Covid pandemic have ushered in a…
10 Analysts Have This to Say About Moderna
Latest Ratings for MRNA
DateFirmActionFromTo Mar 2022Deutsche BankMaintainsHold Feb 2022Morgan StanleyMaintainsEqual-Weight Feb 2022SVB LeerinkMaintainsUnderperform
View…
Moderna, Merck win priority designation for personalized cancer vaccine in EU
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Herstellung bis 2030 geplant: Moderna entwickelt Krebsimpfstoff
Die Forschung an Krebs-Vakzinen läuft weltweit auf Hochtouren. Neben dem Mainzer Biotechnologieunternehmen Biontech arbeitet auch die US-Firma Moderna an einem…
Insiderhandel: Chief Executive Officer verkauft Aktien von Moderna im Wert von 6.298.950$
Bancel, Stephane - Vorstand - Tag der Transaktion: 2023-04-06...…
Insiderhandel: Chief Executive Officer verkauft Aktien von Moderna im Wert von 6.185.585$
Bancel, Stephane - Vorstand - Tag der Transaktion: 2023-04-05...…
IRW-News: Moderna Inc.: Moderna: Europäische Arzneimittelagentur erteilt für MRNA-4157/V940, einen personalisierten MRNA-Prüfimpfstoff gegen Krebs, in Kombination mit Keytruda(R) (Pembrolizumab) den Status eines prioritären Arzneimittels (PRIME) für die adjuvante Behandlung von Patienten mit Hochrisiko-Melanomen der ...
IRW-PRESS: Moderna Inc.: Moderna: Europäische Arzneimittelagentur erteilt für MRNA-4157/V940, einen personalisierten MRNA-Prüfimpfstoff gegen Krebs, in Kombination…
Moderna, Merck Combined Treatment Gets EMA Designation for Melanoma
Moderna, Merck Combined Treatment Gets EMA Designation for Melanoma...…
Moderna, Inc.: MRNA-4157/V940, an Investigational Personalized MRNA Cancer Vaccine, in Combination With Keytruda , Receives Prime Scheme Designation From the European Medicines Agency for Adjuvant Treatment of Patients With High-Risk Stage III/IV Mel
Designation based on positive data from Phase 2b KEYNOTE-942/mRNA-4157-P201 trial and unmet need for additional therapeutic options for certain types…